GTCbio, San Francisco, CA
December 3-4, 2007
With in-house research failing to fill pharma pipelines and a significant number of existing products coming off patent, R&D in the CNS space increasingly relies on partnering and licensing strategies in order capitalize on new discoveries. This meeting will explore key strategic issues facing pharmaceutical and biotechnology licensing and business development executives involved with CNS and CNS related diseases. Attendees will receive first-hand information including case studies of successful strategic alliances, joint presentations on recent deals and exclusive insights into emerging targets. Please bring this conference to the attention of your colleagues and business associates. Take advantage of our “Register 2, the 3rd goes free” offer and bring your entire team. We look forward to welcoming you in December to GTCbio`s CNS: Partnering, Licensing & Deal-making Summit in San Francisco, CA.
|
|
|
Invited Speakers:
|
|
Christine T. Fischette, Ph.D.
Head Negotiation, Neuroscience Business Franchise Board
Global Business Development and Licensing
Novartis Pharmaceuticals Corporation
Martin R. Tolar
ice President, Strategic & Corporate Development
CoMentis
David A. Lowe Ph.D.
Chief Scientific Officer
Memory Pharmaceuticals Corporation
Martin Eglitis
Senior Manager, Licensing
Amgen
Tom Base
Executive Director, Business Development & Operations
CHDI
Paul Ranson Stringer Saul LLP
Leslie Coney
Associate Director of Technology Transfer
Biogen Idec
Adrian J. Carter, MBA
Corporate Division Licensing
Boehringer Ingelheim GmbH
|
|